Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Long-Term Deferred Tax: 2014-2024

Historic Long-Term Deferred Tax for Theravance Biopharma (TBPH) over the last 1 years, with Dec 2024 value amounting to $2.4 million.

  • Theravance Biopharma's Long-Term Deferred Tax fell 99.46% to $2.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.4 million, marking a year-over-year decrease of 99.46%. This contributed to the annual value of $2.4 million for FY2024, which is 99.46% down from last year.
  • Theravance Biopharma's Long-Term Deferred Tax amounted to $2.4 million in Q4 2024, which was down 99.46% from $447.3 million recorded in Q4 2023.
  • Theravance Biopharma's Long-Term Deferred Tax's 5-year high stood at $447.3 million during Q4 2023, with a 5-year trough of $2.4 million in Q4 2024.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $440.7 million (2022), whereas its average is $296.8 million.
  • As far as peak fluctuations go, Theravance Biopharma's Long-Term Deferred Tax grew by 1.49% in 2023, and later tumbled by 99.46% in 2024.
  • Quarterly analysis of 3 years shows Theravance Biopharma's Long-Term Deferred Tax stood at $440.7 million in 2022, then grew by 1.49% to $447.3 million in 2023, then crashed by 99.46% to $2.4 million in 2024.
  • Its Long-Term Deferred Tax was $2.4 million in Q4 2024, compared to $447.3 million in Q4 2023 and $440.7 million in Q4 2022.